Cellebrite Abandons Israeli Registration for U.S. Corporate Redomiciling
Cellebrite is moving its incorporation from Israel to the U.S. in a multi-billion dollar strategic shift aimed at securing major American defense contracts and broadening investor appeal.
Less than two years after the departure of Israeli CEO Yossi Carmil, Cellebrite is delisting from Israel and reincorporating as an American company. The company announced today that its board of directors has approved a corporate reorganization plan, under which a new U.S. company will be established as the group's ultimate parent.
Strategic Reorganization and U.S. Transition
This is a relatively unusual move for a mature company, shifting its place of incorporation from one country to another, a process that typically involves transferring intellectual property out of Israel and into the United States. Cellebrite representatives noted that operations in Israel will continue as usual and no layoffs are expected. The company expects the redomiciling process to be completed by the first half of 2027, subject to successful shareholder approval and regulatory clearances.
Cellebrite is traded on the Nasdaq stock exchange in New York with a market capitalization of approximately $3 billion. Ironically, Carmil, who left Cellebrite after two decades mostly spent leading the firm, stated in a farewell interview that "relocation is the greatest threat to Israeli high-tech," and now Cellebrite itself is making that move.
Business Objectives and Market Position
Cellebrite develops digital investigation and intelligence systems designed for both the private and public sectors. Its name has frequently been linked to human rights controversies, as its software has occasionally been used for surveillance or hacking into the phones of journalists or public and activist figures. Transitioning to a U.S. registration is partly intended to distance Cellebrite as an Israeli company from political headwinds while simultaneously easing its path to securing major defense contracts in the United States.
"Redomiciling is a strategic evolution of our corporate structure. We believe that moving our incorporation to the U.S. will position us better to drive growth across all of our key customer cohorts in our largest geographic market, as well as with other major government clients outside the U.S. This transition will also increase Cellebrite's attractiveness to a broader investor audience through inclusion in key indices."
Shivan Ramji, who was appointed CEO of Cellebrite about a month ago following an interim leadership period since Carmil's departure, highlighted the strategic rationale behind the shift.
